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Classically, allergy depends on IgE antibodies and on high-afﬁnity IgE receptors expressed
by mast cells and basophils.This long accepted IgE/FcεRI/mast cell paradigm, on which the
deﬁnition of immediate hypersensitivity was based in the Gell and Coomb’s classiﬁcation,
appears too reductionist. Recently accumulated evidence indeed requires that not only IgE
but also IgG antibodies, that not only FcεRI but also FcγR of the different types, that not
only mast cells and basophils but also neutrophils, monocytes, macrophages, eosinophils,
and other myeloid cells be considered as important players in allergy. This view markedly
changes our understanding of allergic diseases and, possibly, their treatment.
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INTRODUCTION
A provocative paper was published at the very beginning of the
twentieth century (Richet and Portier, 1902). Louis Pasteur had
just taught the world that immunity is not only the fortune of
those individuals who survived an epidemic and became protected
from that disease. It can be deliberately induced and protect from
all kinds of infections, by variations of an empirical practice pro-
moted one century earlier by Edward Jenner to prevent small pox.
Immunity is not a privilege. Anyone can be immunized, and thus
protected. But in 1901, Charles Richet and Paul Portier make a
disturbing observation. Instead of protecting, an immunization
with a low dose of toxin can induce a state of hypersensitivity,
which kills a dog within minutes following a second exposure to
the same harmless dose of toxin. They repeat their experiments,
they conﬁrm their observation with another toxin, they convince
themselves that they have unraveled a new phenomenon. They
name it anaphylaxis, i.e., the opposite of Pasteur’s prophylaxis. The
fame of Pasteur is immense, worldwide. Richet and Portier have
the intellectual courage to publish their ﬁnding: immunity is not
necessarily protective, it can be deleterious and even kill. Charles
Richet was awarded the Nobel price in Physiology or Medicine in
1913 “for his work on anaphylaxis.”
Anaphylaxis was soon understood as a hyper-acute systemic
allergic syndrome and, since then, unique mechanisms were
searched for to explain this paradoxical response of the immune
system that generates disease when reacting to substances of the
environment as innocuous as pollen, cat hair, house dust, or
even food. In 1910, histamine, a substance isolated from rye pin,
was found to reproduce anaphylactic symptoms (Dale and Laid-
law, 1910). In the 1950s, histamine was found in cells present
as a minor population in tissues (Riley, 1953) and, in the 1960s,
these mast cells were shown to degranulate and to release hista-
mine upon challenge with antibody and antigen (Prouvost-Danon
et al., 1966). In 1966, a unique Erythema–wheal reaction-inducing
Immunoglobulin (IgE), present in minute amounts in plasma
(Ishizaka et al., 1966) but, luckily, secreted in large amounts by a
rare plasmocytoma (Johansson and Bennich, 1967), was described
and reported to account for allergic reactions (Bennich et al.,
1969). IgE were found to be cytotropic, i.e., to bind to cells (Evans
and Thomson, 1972), and in the 1970s, a receptor with a uniquely
high-afﬁnity for IgE was described on mast cells and basophils
(Kulczycki and Metzger, 1974), which was named FcεRI, cloned in
1989 (Blank et al., 1989), and the 3D structure of which was solved
in 1998 (Garman et al., 1998). The allergen-IgE-FcεRI-mast cell-
histamine-clinical symptoms sequence became the paradigmof an
allergic reaction. It accounted for Type I Hypersensitivity and was
enclosed in the Gell and Coombs’ classiﬁcation (Gell and Coombs,
1963). The term initially coined by Clemens von Pirquet after the
Greek words α
,
'λλoς ε
,
'ργoν (allos ergon) to designate the altered
response to a given substance induced by a previous contact with
that substance (von Pirquet, 1906), became increasingly used with
its etymological meaning: allergy is another reaction.
In the early 1950s, however, Zoltan Ovary described passive
cutaneous anaphylaxis (PCA) and used it as a sensitive technique
(Ovary, 1952) to study the IgG antibodies that are responsible for
this in vivo reaction in guinea pigs (Ovary et al., 1960), rabbits
(Warner and Ovary, 1970), rats, and mice (Ovary et al., 1975).
The same IgG antibodies were then shown to activate rat and
mouse mast cells in vitro (Vaz and Prouvost-Danon, 1969), and
IgG receptors were described on these cells (Tigelaar et al., 1971).
When,much later, the ﬁrst knock-outmicewere generated, a paper
reported that active systemic anaphylaxis (ASA) could be induced
in IgE-deﬁcient mice (Oettgen et al., 1994). IgE are not alone, and
much more IgG antibodies are produced together with IgE, what-
ever the immunization protocol used. Antibodies other than IgE
contribute to allergic responses. Likewise, evidence accumulated
that mast cells and basophils work in concert with eosinophils,
neutrophils, monocytes, T cells and NK cells to mount allergic
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inﬂammation. Conversely, mast cells and IgE are involved in bio-
logical responses other than allergy. The Gell and Coombs boxes
were not sealed off. Cells of different types and antibodies of dif-
ferent classes sneaked in and out. Like other antibody-dependent
inﬂammatory diseases, allergy involves the same molecular and
cellular effectors as protective immunity.
MAST CELLS BEYOND ALLERGY
We know now that we have two immune systems. The innate
immune system is made of a large number of differentiated
cells of several types, mostly of the myeloid lineage, equipped
with pattern-recognition receptors that can induce a variety of
responses to pathogens without delay. The adaptive immune sys-
tem is essentially made of limited numbers of lymphoid cells
equipped with antigen receptors, which need to proliferate and
to differentiate into effector cells of different types before they can
act on speciﬁc antigens (Figure 1).
MAST CELLS AS EFFECTORS OF INNATE IMMUNITY
Mast cells have increasingly been recognized as effector cells of
innate immunity. Located everywhere in the body, but particu-
larly at interfaces with the external world and near blood vessels,
FIGURE 1 |The interplay between myeloid and lymphoid cells in
adaptive immune responses. Adaptive immune responses are initiated by
the presentation of antigen by dendritic cells (DC). Cognate interactions
with antigen-presenting cells activate naive T cells that proliferate and
differentiate. TH cells collaborate with speciﬁc B cells that proliferate and
differentiate into Plasma Cells (P) that secrete antibodies (Induction phase).
Antibodies diffuse throughout the body. When interacting with Fc
Receptor-expressing myeloid cells and with speciﬁc antigen, antibodies
induce a wide array of biological responses that depend on the cell type
(Effector phase).
they contribute to protect against pathogens (reviewed in Abra-
ham and St John, 2010). They are further recruited to infection
sites. Mouse and human mast cells express Toll-like and NOD-like
receptors through which pathogen-associated molecular patterns
and proteoglycans induce them to release proteases and to secrete
cytokines, chemokines, and growth factors (Supajatura et al.,
2002). These, in turn, recruit neutrophils, eosinophils, NK cells
and other cells that form an inﬂammatory inﬁltrate (Supajatura
et al., 2001). Mouse mast cells also produce bactericidal peptides
such as cathelicidin (Di Nardo et al., 2003). These mechanisms
altogether account for the critical in vivo protective roles of mast
cells in infection, unraveled by the cecum ligation and puncture
model of acute peritonitis (Echtenacher et al., 1996) and by bac-
terial challenge (Supajatura et al., 2001). Rat mast cells have also
been associated with helminth infection during which they pro-
liferate in response to stem cell factor (SCF), and they contribute
to worm expulsion by several mechanisms (Levy and Frondoza,
1983; Woodbury et al., 1984).
More recently, mouse mast cells were found to protect from
honeybee, snake, lizard, and scorpion venoms. Venoms indeed
induce mast cell degranulation and they are degraded by proteases
contained in granules. Thus, carboxypeptidase A3 hydrolyzes the
venom peptide sarafotoxin 6b (Metz et al., 2006) and the related
mammalian vasoconstrictor peptide endothelin-1 (Maurer et al.,
2004), while chymase mast cell protease 4 hydrolyzes the lizard
venom helodermin and the related mammalian vaso-intestinal
peptide (Akahoshi et al., 2011).
With and like dendritic cells (DC), mast cells are involved in
the initiation of adaptive immunity. Mouse mast cells promote
DC differentiation and, by up-regulating E-selectin expression on
vascular endothelium cells, the inﬂux of monocyte-derived DC
(Shelburne et al., 2009). Mouse mast cell products modulate DC
activation and antigen presentation (Amaral et al., 2007), lead-
ing to a skewed Th2 cell differentiation (Mazzoni et al., 2006).
Whether mast cells themselves can present antigen has long been
unclear as major histocompatibility class II (MHC-II) molecules
were not found on fresh peritoneal mouse mast cells (Daëron and
Voisin, 1979) or on bone marrow-derived mast cells (BMMC) cul-
tured with IL-3 (Frandji et al., 1995). Recently, however, it was
shown that MHC-II could be induced by IFN-γ and IL-4 on
mouse peritoneal mast cells and on peritoneal cell-derived mast
cells (PCMC; Gaudenzio et al., 2009), a cultured model of mature
serosal-type mast cells that resemble peritoneal mast cells (Mal-
bec et al., 2007), but not on BMMC. When loaded with antigen,
such cytokine-primed MHC-II+ mast cells could establish cog-
nate interactions with CD4+ T cells for antigen presentation and
bidirectional cell–cell cooperation (Valitutti and Espinosa, 2010),
resulting in T cell activation and enhanced responsiveness of mast
cells to IgE-induced activation.
MAST CELLS AS EFFECTORS OF ADAPTIVE IMMUNITY
Mast cells are involved not only in the induction phase, but also
in the effector phase of adaptive immunity. Adaptive immune
responses generate effector cells and molecules. Cells include
antigen receptor-expressing T cells, endowed with various effec-
tor functions, and capable of secreting numerous antigen-non-
speciﬁc cytokines upon cognate interactions with speciﬁc antigen.
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B cell-derived plasma cells have no antigen receptor, but they
secrete high amounts of antigen-speciﬁc antibodies that reach the
bloodstream and diffuse in the whole body (Figure 1).
Antibodies, however, have no biological activity by themselves.
Their Fab portions can bind to antigens with a variable speciﬁcity
and afﬁnity, but except in rare instances, binding to antigen has
little or no biological consequences. Therapeutic antibodies raised
against receptors (Li et al., 2005) or ligands (Ellis and Hicklin,
2008) can prevent ligand–receptor interactions and some anti-
receptor antibodies can mimic agonists (Shan et al., 2000). It was
recently shown,however, that to“neutralize”bacterial toxins (Joller
et al., 2010) or viruses (Mallery et al., 2010), antibodies require that
their Fc portion binds to cellular receptors that transport immune
complexes to intracellular compartmentswhere they are degraded.
For antibodies to affect antigens, they indeed not only need to bind
to antigens through their Fab portions, but also to interact through
their Fc portion with effector systems. Among these are the many
cells,mostly of hematopoietic origin, that express receptors for the
Fc portion of antibodies (FcR). FcR provide these cells,which have
no antigen receptors, with B Cell Receptor-like immunoreceptors
and a bona ﬁde immunological speciﬁcity (Daëron, 1997). Impor-
tantly, this speciﬁcity is an intrinsic property neither of the cell
nor of the FcR, but of antibodies. When binding to FcR, speciﬁc
antibodies enroll the effector cells of innate immunity in adaptive
immunity (Figure 1). Mast cells are such cells.
ANTIBODY RECEPTORS EXPRESSED BY MAST CELLS AND
OTHER MYELOID CELLS
FcR are immunoreceptors of the third type. If the BCR enables B
cells to interactwith native antigen and if theTCR enables T cells to
interact with antigen-derived peptides associated with MHC mol-
ecules, FcR enable a variety of cell types to interact with antigen
under the form of immune complexes. These can thus stimu-
late and/or control a variety of biological responses that primarily
depend on the cell type. Besides high-afﬁnity IgE receptors, mast
cells and basophils share several antibody receptors with other
myeloid cells.
HIGH- AND LOW-AFFINITY FcR
Antibodies bind to FcR with a variable afﬁnity (Hulett and Hog-
arth, 1994). A proportion of high-afﬁnity FcR, which can bind
monomeric immunoglobulins in the absence of antigen, are occu-
pied in vivo whereas low-afﬁnity FcR, which can bind antibodies
as multivalent immune complexes only, are not in spite of the high
concentration of circulating immunoglobulins.
High-afﬁnity FcR include IgA (FcαRI, in humans), IgE (FcεRI,
in humans and mice), and IgG receptors (FcγRI, in humans and
mice, and FcγRIV, in mice only). Low-afﬁnity FcR include IgE
(FcεRII, in humans and mice) and IgG receptors (FcγRII and III,
in humans and mice). Humans have three FcγRII (FcγRIIA, B,
and C), and two FcγRIII (FcγRIIIA and B) whereas mice have one
receptor of each type (FcγRIIB and FcγRIIIA) only. The diversity
of human FcγRII and III is further increased by polymorphisms
of speciﬁc residues in their extracellular domains (Figure 2).
The afﬁnity constant (K a) of mouse and human FcεRI for
IgE is 109–10 M−1 (Kulczycki and Metzger, 1974; Metzger, 2004);
those of human and mouse FcγR for human and mouse IgG sub-
classes, respectively, span from ±105 to 108 M−1 (Figure 3; Bruhns
et al., 2009). Noticeably, low-afﬁnity interactions were described
between IgE and IgG receptors. Mouse IgE can bind to mouse
FcγRIIB and FcγRIIIA with a K a ± 2× 104 M−1 (Takizawa et al.,
1992) and to FcγRIV with a K a ± 3× 105 M−1 (Mancardi et al.,
2008; Figure 3).
FcR SIGNALS
FcR trigger no signal when binding immunoglobulins. They signal
when aggregated on the cell membrane by antibodies and pluri-
valent antigens (Maeyama et al., 1986; Metzger, 1992). Although
the result is the same, the sequence of events that lead to recep-
tor aggregation is different for high-afﬁnity and low-afﬁnity
FIGURE 2 | Murine and human receptors for the Fc portion (FcR) of IgE and IgG.This ﬁgure schematizes FcR for IgE and for IgG expressed by mouse and
human myeloid cells.
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FIGURE 3 | Affinity of mouse and human FcR for homologous IgE and IgG subclasses. Afﬁnity constants were determined by Plasmon resonance analysis.
(Dierks et al., 1993; Hibbert et al., 2005; Nimmerjahn and Ravetch, 2005; Mancardi et al., 2008; Bruhns et al., 2009).
FcR. Monomeric antibodies bind ﬁrst to high-afﬁnity FcR that
are aggregated when a plurivalent antigen binds to receptor-
bound antibodies. Antibodies bind ﬁrst to antigen, generating
immune complexes that can bind to and, therefore, simultaneously
aggregate low-afﬁnity FcR.
FcR can trigger activation signals and/or inhibition signals. The
nature of signals primarily depends on molecular motifs con-
tained in the intracytoplasmic domains of FcR or of receptor
subunits with which FcR associate. Two such motifs were iden-
tiﬁed. Immunoreceptor tyrosine-based activation motifs (ITAM)
consist of two YxxL motifs separated by a six to eight variable
amino acid sequence (Reth, 1989). Immunoreceptor tyrosine-
based inhibition motifs (ITIM) consist of a single YxxL motif
preceded by a loosely conserved often hydrophobic residue at
position Y-2 (Vivier and Daëron, 1997).
Activating FcR are FcαRI, FcεRI, FcγRI, FcγRIIA, FcγRIIC,
FcγRIIIA, and FcγRIV. FcγRIIA and FcγRIIC are single-chain
receptors the intracytoplasmic domains of which are identical and
contain an ITAM. FcαRI, FcεRI, FcγRI, FcγRIIIA, and FcγRIV
associate with the common FcR subunit FcRγ (Daëron, 1997).
FcRγ is a homodimer that contains two ITAM (Orloff et al., 1990).
FcεRI also associatewith another subunit namedFcRβ (Kinet et al.,
1988). FcRβ is a tetraspanin that contains an ITAM. Upon recep-
tor aggregation, ITAM are phosphorylated by src-family tyrosine
kinases (Pribluda et al., 1994), which initiates the constitution of
dynamic intracellular signalosomes (Kent et al., 1994) in which
activation signals are dominant over inhibition signals (Malbec
et al., 2004).
Inhibitory receptors are FcγRIIB. FcγRIIB are single-chain
receptors the intracytoplasmic domain of which contains one
ITIM (Daëron et al., 1995a). Unlike activating receptors, FcγRIIB
trigger no intracellular signal upon aggregation. They trigger nega-
tive signalswhen they are coaggregatedwith activating receptors by
immune complexes (Daëron et al., 1995b).Under these conditions,
the ITIM of FcγRIIB is phosphorylated by the same src-family
tyrosine kinase that phosphorylates ITAM in activating receptors
(Malbec et al., 1998). Phosphorylated FcγRIIB recruit inhibitory
molecules that are brought into signalosomes. This renders inhi-
bition signals dominant over activation signals (Lesourne et al.,
2005; Daëron and Lesourne, 2006).
BIOLOGICAL RESPONSES INDUCED BY FcR AND THEIR TISSUE
DISTRIBUTION
Activating FcR can trigger a variety of cellular responses, including
the endocytosis of soluble immune complexes, the phagocytosis of
particulate complexes, the exocytosis of preformed granularmedi-
ators, including vasoactive amines, proteolytic enzymes, and/or
cytotoxicmolecules, the production of newly formed lipid-derived
pro-inﬂammatory mediators or the secretion of newly transcribed
cytokines, chemokines, and growth factors. The nature of biolog-
ical responses triggered by antibodies via FcR primarily depends
on the cell type. They are indeed determined by the functional
repertoire of the cell and, therefore, by the tissue distribution
of FcR. Except NK cells that express FcγRIIIA only, B cells that
express FcγRIIB only, and T cells that express none, other cells of
hematopoietic origin co-express several FcR and, in most cases,
activating and inhibitory FcR. FcγRIIB, however, have a more
restricted tissue distribution in humans than in mice. In both
mice and humans, mast cells, and basophils express constitutively
not only high-afﬁnity FcεRI, but also low-afﬁnity FcγR of several
types (Figure 4).
Multi-chain FcR need to associate with FcRγ in order to
reach the plasma membrane. Their intracytoplasmic domain
indeed contains a retention site that sequesters the polypeptide
in the endoplasmic reticulum, unless it associates with FcRγ
(Lobell et al., 1993; Letourneur et al., 1995). The expression of
these receptors therefore depends on the tissue distribution of
FcRγ, and FcRγ-deﬁcient mice have no activating FcR (Takai
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FIGURE 4 |Tissue distribution of mouse and human FcR for IgE and IgG.
The ﬁgure shows the relative expression of activating (red) and inhibitory
(blue) IgE and IgG receptors of the immunoglobulin superfamily by murine
and human hematopoietic cells. Gray bars show the expression of FcγRIIIB.
et al., 1994). Mouse FcεRI, but not human FcεRI, also need
to associate with FcRβ (Kinet, 1999). As FcRβ is expressed by
mast cells and basophils only in both species, the expression
of FcεRI is restricted to these cells in mice but not in humans
(Gounni et al., 1994, 2001; Joseph et al., 1997). Noticeably,
mouse FcγRIIIA, the expression of which requires FcRγ but not
FcRβ, associate with both subunits in mast cells (Kurosaki et al.,
1992).
DIFFERENTIAL EFFECTS OF IgG ANTIBODIES IN MAST CELLS
AND BASOPHILS
The pattern of FcR expression enables mast cells to be activated
not only by IgE, but also by IgG antibodies. IgE-induced responses
of mast cells and basophils are well known. IgG-induced responses
of mast cells are less known. Likewise, basophils co-express recep-
tors for IgE and IgG. Unlike mast cells, however, basophils are not
activated by IgG.
MAST CELL RESPONSES TO IgG ANTIBODIES
Besides FcεRI, mouse mast cells express constitutively, FcγRIIB
and FcγRIIIA (Benhamou et al., 1990). As FcεRI and FcγRIIIA
are expressed in association with the same subunits in mouse
mast cells, they can trigger the same biological responses. The
aggregation of mouse FcγRIIIA was demonstrated to trigger both
the release of serotonin (Daëron et al., 1992) and the secretion
of TNF-α (Latour et al., 1992) when expressed in rat basophilic
leukemia (RBL) 2H3 transfectants. Likewise, the engagement of
FcγRIIIA on BMMC or on PCMC triggered a release of β-
hexosaminidase and a secretion of TNF-α (Malbec et al., 2007).
FcεRI- and FcγRIIIA-dependent responses of BMMC were qual-
itatively similar (they released the same granular mediators and
secreted the same cytokines). IgE- and IgG-induced responses
were quantitatively similar in mouse peritoneal mast cells and
in PCMC.
Although mouse BMMC and PCMC express similar amounts
of FcγRIIB and FcγRIIIA, PCMC can be readily activated by IgG
immune complexes, but not BMMC. The reason is that FcγRIIB
has a potent inhibitory effect on FcγRIIIA-dependent activation
in BMMC, but a much milder one in PCMC. FcγRIIB-deﬁcient
BMMC indeed responded similarly to IgG immune complexes as
FcγRIIB-deﬁcient PCMC, and both mast cell types contained sim-
ilar amounts of the SH2 domain-containing inositolphosphatidyl
5-phosphatase SHIP1 that accounts for FcγRIIB-dependent neg-
ative regulation (Ono et al., 1996; Huber et al., 1998). The differ-
ence was that, for an unknown reason, BMMC use SHIP1 more
efﬁciently than PCMC (Malbec et al., 2007).
Besides FcεRI, human skin mast cells express constitutively
FcγRIIA (Ghannadan et al., 1998; Zhao et al., 2006). All human
mast cells, however, may not express FcγRIIA as lung mast cells
were reported to be CD32-negative (Agis et al., 1996). Human
cord blood-derived mast cells (CBMC) were reported to express
FcγRIIB (Kepley et al., 2004), but not skin-derived human mast
cells (Zhao et al., 2006). Because they reside in tissues, mast cells
are not readily accessible in humans. Tissue samples obtained fol-
lowing surgery are the only available source of mature humanmast
cells. Although, like mouse BMMC, they are immature cells that
have no known physiological equivalent, CBMC have been more
often used. CBMC express FcγRIIA (our unpublished observa-
tion) and FcγRIIB (Kepley et al., 2004). The human mast cell
line HMC-1 also expresses FcγRIIA, but no FcεRI. The aggre-
gation of FcγRIIA with speciﬁc antibodies induced the release
of serotonin by RBL-2H3 transfectants (Daëron et al., 1995a).
The engagement of FcγRIIA by IgG immune complexes triggered
peritoneal mast cells and PCMC from FcγRIIA-transgenic mice
to degranulate and to release histamine (Jönsson et al., 2011b).
Finally, anti-FcγRIIA antibodies triggered human skin-derived
mast cells to release histamine (Jönsson et al., 2011b) and to secrete
lipid-derived mediators and cytokines (Zhao et al., 2006).
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In addition to low-afﬁnity IgG receptors, high-afﬁnity IgG
receptors (FcγRI) couldbe inducedby IFN-γonhuman (Okayama
et al., 2000), but not on mouse (Tan et al., 2003) mast cells,
and it was found on skin mast cells from lesions of psori-
asis patients (Tkaczyk et al., 2002) and intestinal mast cells
from Crohn’s disease patients (Kobayashi et al., 2007). These
receptors associated with the FcRγ subunit in IFN-γ-treated
human mast cells. Whether they also associated with FcRβ is
unknown. FcγRI aggregation induced the release of histamine,
the production of prostaglandin D2 and leukotriene C4, and
the secretion of IL-3, IL-13, TNF-α, and GM-CSF by IFN-γ-
treated human mast cells (Okayama et al., 2001; Tkaczyk et al.,
2002).
BASOPHIL RESPONSES TO IgG ANTIBODIES
Besides FcεRI, mouse basophils express constitutively FcγRIIIA
and FcγRIIB, i.e., the same FcR as mouse mast cells. Unlike
PCMC, but like BMMC, they fail to respond to IgG immune com-
plexes. This absence of response results from an active inhibition
of FcγRIIIA-dependent activation signals by FcγRIIB. Basophils
fromwtmice indeed secreted IL-4 in response to FcγRIIIA engage-
ment by FcγRIIIA-speciﬁc antibodies or by IgG immune com-
plexes when FcγRIIBwere blocked by a FcγRIIB-speciﬁc antibody.
Conﬁrming these results, basophils from FcγRIIB-deﬁcient mice
secreted high amounts of IL-4 in response to IgG immune com-
plexes. FcγRIIB therefore prevent mouse basophils to respond to
IgG antibodies (our unpublished data).
Besides FcεRI,humanbasophils express constitutively FcγRIIA,
FcγRIIB (Kepley et al., 2000), and small amounts of FcγRIIIB
(Meknache et al., 2009). Basophils from normal donors could be
readily activated, as assessed by CD203c up-regulation and his-
tamine release, upon FcεRI engagement with F(ab′)2 fragments
of anti-IgE antibodies. They were not detectably activated upon
FcγRIIIB engagement by F(ab′)2 fragments of anti-FcγRIIIB anti-
bodies (Meknache et al., 2009). Whether the absence of response
to FcγRIIIB engagement is due to the very low expression of this
receptor on basophils (10- to 100-fold lower than on neutrophils)
or by the inability of this glycosylphosphatidyl-anchored receptor
to trigger activation signals by itself is unclear. Normal basophils
could be also activated by F(ab′)2 fragments of anti-FcγRIIA
antibodies, especiallywhen cellswereprimedby anovernight incu-
bation with human IL-3, but much less than by anti-IgE. They
failed to detectably respond when challenged with IgG immune
complexes or heat-aggregated human IgG, even if primed with
IL-3. The poor response of basophils to anti-FcγRIIA antibod-
ies and their absence of response to IgG immune complexes can
be explained by the relative expression of FcγRIIA and FcγRIIB,
respectively.We indeed found that humanbasophils are among the
blood cells that display the lowest levels of FcγRIIA, and that they
expressmore FcγRIIB than any other blood cells (our unpublished
data).
Like mouse basophils but, probably not for the same reason,
human basophils therefore do not respond to IgG antibodies. It
follows that FcγR do not exert the same functions in mast cells and
basophils:whenFcγRare engagedby IgG immune complexes, acti-
vation is dominant in mast cells whereas inhibition is dominant
in basophils.
MAST CELLS AND BASOPHILS IN IN VIVO MODELS OF
ALLERGY AND AUTOIMMUNITY
Contrastingwith the in vitro properties of mast cells and basophils,
their contribution to human diseases or even to murine models
of human disease has been more difﬁcult to delineate. One rea-
son is that, until very recently, there was no satisfactory mean to
investigate the contributions of mast cells and basophils in vivo.
STRENGTHS AND WEAKNESSES OF AVAILABLE TOOLS USED TO
EVALUATE THE CONTRIBUTION OF MAST CELLS AND BASOPHILS IN
IN VIVO MODELS OF INFLAMMATORY DISEASES
Chemical tools, so called mast cell stabilizers, like cromolyn, keto-
tifen or tranilast, have been used to treat asthmatic and other aller-
gic patients for almost three decades (Patalano and Ruggieri, 1989;
Ruggieri and Patalano, 1989). They have sometimes been used also
as pharmacological inhibitors of mast cell functions (Costa-Pinto
et al., 2007; Kano et al., 2008). The mechanism by which these
drugs inactivate mast cells is poorly understood and, cromolyn
also affects eosinophils and neutrophils. Results obtained using
such tools are therefore difﬁcult to interpret (Moqbel et al., 1986).
More importantly, mast cell-deﬁcient mice have been widely
used to investigate the involvement of mast cells in vivo, in a vari-
ety of experimental models of human diseases. There are several
such mice. WCB6F1/J-KitlSl/KitlSl-d (Sl/Sl-d) mice do not express
membrane SCF on ﬁbroblasts and other cells (Zsebo et al., 1990).
WBB6F1-KitW/KitW-v (W/W-v) mice are compound mutants for
the SCF receptor Kit (one allele being null, the other impaired).
C57BL/6-KitW-sh (Wsh) mice carry an inversion of a regulatory
element, leading to Kit deﬁciency, but also to a disruption of the
gene encoding the transmembrane protease corin that is expressed
on cardiomyocytes and regulates blood pressure (Nigrovic et al.,
2008). Experimental diseases that were either abrogated or milder
in these mice than in wt mice were proposed to depend on mast
cells. Data obtained with these mice must, however, be interpreted
with caution. If they are mast cell-deﬁcient, these mice indeed
exhibit numerous additional abnormalities. The reason is that Kit
is expressed not only by mast cells, but also by hematopoietic
progenitor cells, germinal cells, and a few differentiated cells such
as melanocytes and intestinal Cajal cells. Thus, Sl/Sl-d and W/W-v
mice are sterile and anemic. W/W-v mice are neutropenic, they
lack Cajal cells and intraepithelial γδ T cells, they are partially deaf
and prone to dermatitis and gastritis. Wsh mice are fully fertile,
but they frequently develop myeloid and megakaryocytic prolif-
eration in the spleen and bone marrow, resulting in neutrophilia,
basophilia, increased mast cell progenitor numbers in the spleen
and elevated platelet numbers in the blood (Mancardi et al., 2011).
Illustrating the problem, discrepant results were observed in mod-
els of contact hypersensitivity in W/W-v and in Wsh mice (van
Loveren et al., 1983; Galli and Hammel, 1984; Mekori and Galli,
1985; Biedermann et al., 2000; Grimbaldeston et al., 2007).
In view of the many abnormalities that affect Kit-mutant mice,
the conclusion that an experimental process depends on mast cells
because it does not occur in suchmice is generally conﬁrmedby the
demonstration that it can be restored if deﬁcientmice are reconsti-
tuted with mast cells. Conclusions drawn from these experiments
must, however, also be taken with caution. Cultured mast cells,
i.e., essentially BMMC, are commonly used to reconstitute mast
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cell-deﬁcient mice, and reconstitution requires long periods of
time (usually 8–12weeks). Reconstitution is rarely complete and
it greatly varies with the anatomical site (Grimbaldeston et al.,
2005). In addition, BMMC are immature cells, and even after pro-
longed differentiation in IL-3 containing culture, theymay contain
residual pluripotent hematopoietic progenitors. What happens to
these cells after they are injected is unknown, and the possibility
that an in vivo differentiation into cells other thanmast cells occurs
cannot be excluded.
Another approach to determine the in vivo roles of mast cells
and basophils consists of depleting these cells by injecting mice
with speciﬁc antibodies. Thus, studies that used the anti-mouse
FcεRI mAb MAR-1 or the anti-mouse CD117 (Kit) mAb ACK2,
led to the conclusion that mast cells, which express both FcεRI
and Kit, are required for experimental oral allergen-induced diar-
rhea (Brandt et al., 2003). Antibody-induced mast cell depletion
has several drawbacks. Indeed, no mast cell-speciﬁc antibody is
available. MAR-1 has been extensively used to delete basophils
(Denzel et al., 2008; Sokol et al., 2008, 2009; Perrigoue et al.,
2009; Yoshimoto et al., 2009). Since it targets FcεRI-expressing
cells, it however depletes also mast cells. Furthermore, its speci-
ﬁcity is questionable as it depletes DC as well (Hammad et al.,
2010). ACK2 targets all Kit-expressing cells, i.e., mast cells, Cajal
cells, and hematopoietic stem cells. Likewise, the anti-CD200R3
antibody Ba103 was reported to selectively delete basophils when
injected intravenously (Obata et al., 2007). CD200R3 is however
expressed not only by basophils, but also by mast cells (Obata
et al., 2007). CD200R3 functions as an activating receptor whose
transmembrane domain contains a lysine residue that is likely to
mediate its association with an ITAM-containing subunit such as
FcRγ or DAP12 and, indeed, Ba103 activates both basophils and
mast cells in vitro (Kojima et al., 2007). How it depletes basophils is
unknown. mAb-induced cell depletion is thought to involve acti-
vating FcγR-expressing effector cells through antibody-dependent
cell-mediated cyotoxicity (ADCC). One may wonder whether, fol-
lowing intensive ADCC, the function of these cells, which are
critical in inﬂammation, might not be altered for subsequent
experiments. Finally one can also wonder about the in vivo conse-
quences of a massive release of biologically active molecules stores
in the granules of cells when mast cells and basophils are either
systemically activated or destroyed by ADCC.
Because of the many difﬁculties discussed above, we chose to
use another approach to investigate the in vivo contributions of
mast cells and other myeloid cells in anaphylaxis. This approach
consists of using mice whose mast cells and basophils are normally
present, but cannot respond to a given stimulus because they lack
the necessary receptors. Thus, mast cells and basophils cannot
respond to IgG antibodies in FcγRIIB−/−FcγRIIIA−/− mice, but
cells that, unlike mast cells, express FcγRIV, and/or FcγRI can.
The differential tissue distribution of the various FcR (Figure 4)
can thus be exploited to dissect the relative in vivo contributions
of different cell types in experimental models of inﬂammatory
diseases.
Recently, genetically modiﬁed mice have been generated that
enable mast cells and/or basophils to be selectively targeted
using promoters of proteases speciﬁcally expressed in one cell
type or the other (Table 1). Mcpt5 (Scholten et al., 2008),
Cpa3 (Feyerabend et al., 2009, 2011; Lilla et al., 2011), or chymase
(Musch et al., 2008) were used to target mast cells, whereas Mcpt8
(Ohnmacht et al., 2010; Wada et al., 2010; Sullivan et al., 2011)
was used to target basophils. Cell deletion was either inducible
or constitutive. Cells expressing the diphtheria toxin receptor
(DTR) were depleted following diphtheria toxin-α (DTA) injec-
tion, whereas cells expressing DTA were deleted constitutively.
Another system, based on the use of the Cre recombinase, hap-
pened to lead to the selective constitutive destruction of cells that
express highCre levels, due toCre toxicity.Mast cells and basophils
are such cells when Cre is under the control of the Cpa3 (Feyer-
abend et al., 2011) or Mcpt8 (Ohnmacht et al., 2010) promoters,
respectively. A variation of this system was very recently reported,
inwhich aﬂoxed anti-apoptotic factorwas deleted inmast cells and
basophils that expressed Cre under the control of Cpa3 (Lilla et al.,
2011). Using the Mcpt5 promoter to control either DTR or DTA
expression, led to the selective depletion of skin and peritoneal
mast cells, i.e., of connective tissue mast cells (CTMC; Dudeck
et al., 2011), whereas using the Cpa3 promoter to control Cre
expression led to the depletion of both CTMC and mucosal mast
cells (MMC; Feyerabend et al., 2011; Lilla et al., 2011). The lat-
ter system also led to the depletion of a signiﬁcant proportion of
basophils. When under the control of the chymase promoter, Cre
was selectively expressed in MMC (Musch et al., 2008). These mice
should enable one to deplete MMC only when crossed with mice
expressing DTR or DTA. Using the Mcpt8 promoter to control the
expression of DTR (Wada et al., 2010), DTA or Cre (Ohnmacht
et al., 2010) led to the selective depletion of basophils (Table 1).
Due to the above-discussed limitations of the approaches pre-
viously used to study mast cell function in vivo, some conclusions
on the role of mast cells in allergic and autoimmune inﬂamma-
tion have been challenged by other approaches, and they need to
be reconsidered.
MAST CELLS IN AUTOIMMUNE INFLAMMATION
Indirect evidence suggests that FcγR-dependent mast cell acti-
vation is critical in IgG-induced autoimmune diseases, both in
mouse models and in patients. Numerous mast cells are found
in multiple sclerosis plaques, mast cell-speciﬁc tryptase is ele-
vated in the cerebrospinal ﬂuid (Rozniecki et al., 1995), and FcεRI
and tryptase transcripts, are upregulated in lesions (Pedotti et al.,
2003). Likewise, mast cells were found to accumulate in brain
lesions in experimental allergic encephalomyelitis (EAE), a model
of multiple sclerosis induced by immunizing mice with myelin
or myelin-derived peptides. Clinical symptoms were markedly
decreased, as well as T cell inﬁltrates and IFN-γ production in
W/W-v mice, and they could be restored by BMMC from wt mice,
but not from FcRγ- or FcγRIIIA-deﬁcient mice (Tanzola et al.,
2003).
Mast cells have also been implicated in rheumatoid arthritis,
Sjögren syndrome, systemic sclerosis, and thyroiditis in humans
(Hebbar et al., 1995; Tetlow and Woolley, 1995; Akimoto et al.,
1998; Skopouli et al., 1998; Toda et al., 2000; Hueber et al.,
2010). K/BxN serum-induced arthritis, a mouse model of pas-
sive rheumatoid arthritis (Monach et al., 2007), was abrogated in
FcRγ-deﬁcient mice (Kyburz et al., 2000). It was also abrogated
in W/W-v or in Sl/Sl-d mice, and it was restored by transferring
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Table 1 | Comparison of genetically modified mast cell- and/or basophil-deficient mice.
Mast cell-targeting strategies Basophil-targeting strategies
Mcpt5-Cre+
iDTR
Mcpt5-Cre+
R-DTA+
Cpa3Cre/+ Cpa3-Cre;
Mcl-lfl/fl
Mcpt8DTR Basoph8×
Rosa-DTα
Mcpt8-Cre
Modiﬁcation Transgene Transgene Knock-in Transgene Knock-in Knock-in BAC transgene
Expression in CTMC,
10% NKl.l+,
CD49b+ cells
CTMC,
10% NKl.l+,
CD49b+ cells
MC,
90%T cells,
5% B cells
MC, ∼15%
granulocytes, 5%
T cells & RBC
basophils All basophils, except
in BM discrepancy
between CD49b and
YFP expression
∼15%T cells,
NK cells, DCs,
eosinophils,
80% peritoneal
MC
Deleted cells ∼97% Skin
MC ∼98%
Peritoneal MC
∼90% Skin
MC, ∼98%
Peritoneal MC
CTMC and
MMC
CTMC and MMC ∼90%
Basophils in
skin, spleen,
BM, blood
>90% Basophils >90% Basophils
Deletion Inducible Constitutive Constitutive Constitutive Inducible Constitutive Constitutive
Deletion due
to
DT injection Cre-driven DTA
expression
Cre toxicity Cre-driven
deletion of Mcl-1
DT injection Cre-driven DTA
expression
Cre toxicity
Side effects Not reported Not reported Depletion of
60% spleen
basophils
Depletion of up to
78% basophils
Not reported No effects observed No effects
observed
Remarks Did not look at
basophils
Did not look at
basophils
T or B cell
unaffected
Mild anemia ? MC not affected MC not affected
Responses
affected by
deletion
Early and
delayed-type
contact hyper-
sensitivity to
haptens
Early and
delayed-type
contact hyper-
sensitivity to
haptens
IgE–PCA,
IgE–PSA,
IgE–PCA,
IgE–CAI,
IgE–PSA
Secondary
immune
response to
ticks (H.
longicornis)
Cytokines in
secondary infection
with N. brasiliensis
IgE–CAI, Sec-
ondary immune
response to N.
brasiliensis
Responses
unaffected by
deletion
? ? T cell-
dependent
antibody
response to
hapten–carrier,
K/BxN arthritis,
MOG-induced
EAE
Chronic allergic
inﬂammation of
the airways
IgE–PCA,
Primary
immune
response to
ticks (H.
longicornis)
CD4+ T cell
responses to
IL-4-inducing stimuli
(S. mansoni ; papain),
Worm clearance in
primary and
secondary N.
brasiliensis infection
ASA, IgE–PSA,
IgGl–PSA,
papain-ind.
Th2 responses,
OVA-alum-ind.
allergic lung
inﬂammation,
primary immune
response to N.
brasiliensis
References Scholten et al.
(2008), Dudeck
et al. (2011)
Scholten et al.
(2008), Dudeck
et al. (2011)
Feyerabend
et al. (2009),
Feyerabend
et al. (2011)
Lilla et al. (2011) Wada et al.
(2010)
Sullivan et al. (2011) Ohnmacht et al.
(2010)
BMMC from wt mice (Lee et al., 2002). Zhou et al. (2007) how-
ever reported that antibody-mediated arthritis was not impaired
inWsh mice.We could conﬁrm this result in K/BxN arthritis using
Wsh, but also in mice that lack activating FcR on mast cells (Man-
cardi et al., 2011). Finally, Tsuboi et al. (2011) reported that a
transfer of neutrophils was sufﬁcient to restore K/BxN arthritis in
W/W-v mice.
Very recently, both K/BxN arthritis and EAE were found to
develop normally in Cpa3Cre/+ mice that lack both connective-
type and MMC (Feyerabend et al., 2011). This result strongly
challenges the previously drawn conclusion that mast cells are
mandatory for IgG-induced experimental autoimmune diseases.
It does not exclude that mast cells are involved, but their role
is unknown and their presence in lesions may be a consequence
rather than a cause. Together with previous results obtained inKit-
mutant mice, these recent results also indicate that a Kit deﬁciency
is more critical in experimental arthritis and encephalomyelitis
than a mast cell, and probably, a basophil deﬁciency.
MAST CELLS AND BASOPHILS IN ALLERGY
The role of IgE-induced FcεRI-dependent mast cell activation in
experimental anaphylaxis (Metcalfe et al., 2009; Kalesnikoff and
Galli, 2010) and in allergy (Galli and Tsai, 2010) is well known and
documented. It was recently conﬁrmed in new mast cell-deﬁcient
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mice, as IgE-induced passive systemic anaphylaxis (PSA)was abro-
gated in Cpa3Cre/+ mice and could be restored following recon-
stitution with wt BMMC (Feyerabend et al., 2011). The role of
IgG-induced FcγR-dependent mast cell activation in not as clear
in every experimental model.
Passive cutaneous anaphylaxis is one model that most proba-
bly depends on mast cells only, both when induced with IgE or
with IgG antibodies. IgE-induced PCA (IgE–PCA) was abrogated
in FcεRI-deﬁcient mice (Dombrowicz et al., 1993), inW/W-v mice
(Wershil et al., 1987;Arimura et al., 1990), inWshmice (Zhou et al.,
2007), and in histidine decarboxylase-deﬁcient mice that have
reduced numbers of mast cells which contain no histamine (Ohtsu
et al., 2002). It could be restored by a short-term reconstitution
of mast cell-deﬁcient mice with mast cells injected intradermally
(Wershil et al., 1987). Recently, IgE–PCA was found to be abro-
gated in Cpa3Cre/+ mice (Feyerabend et al., 2011). IgG-induced
PCA was abrogated in FcγRIIIA-deﬁcient (Hazenbos et al., 1996).
We found recently that mouse IgG1-induced or heat-aggregated
human IgG-induced PCA was abrogated in multiple FcR-deﬁcient
mice the mast cells of which expressed no FcγR. PCA was however
observed if these mice were crossed with FcγRIIA-transgenic mice
the mast cells of which expressed this human receptor, but not if
Wsh mice were crossed with the same FcγRIIA-transgenic mice
(Jönsson et al., 2011b).
As expected, mouse IgG1-induced PSA was shown to depend
on FcγRIIIA in mice (Miyajima et al., 1997). Unexpectedly, it
was found not to be abrogated in mast cell-deﬁcient mice and,
therefore, not to depend on mast cells (Miyajima et al., 1997).
The depletion of basophils by Ba103, however, abolished PSA
as assessed by body temperature drop, leading to the conclu-
sion that basophils, but not mast cells, account for IgG1-induced
PSA (Tsujimura et al., 2008). This conclusion, however, was soon
challenged by the ﬁnding that IgG1-induced PSA still occurred
in basophil-deﬁcient Mcpt8-Cre mice (Ohnmacht et al., 2010).
Using FcR-deﬁcient mice that expressed receptors for IgG2 but
no receptor for IgG1, we could show that PSA can be induced
by IgG2 antibodies, that IgG2-induced PSA can occur in the
absence of activating FcR on mast cells and basophils, and that
neutrophils largely contribute to this reaction (Jönsson et al.,
2011a).
The latter observation demonstrates that anaphylaxis may not
depend only on mast cells or basophils. If, indeed, these cells
stand among the myeloid cells involved in inﬂammation, whether
physiological or pathological, and in the latter case, whether aller-
gic or autoimmune, they are not alone. One needs to assess
the contribution of cells other than mast cells and basophils
in both types of diseases. Using FcR-deﬁcient mice whose mast
cells and basophils express no activating FcR, we found an unex-
pected role of neutrophils in systemic anaphylaxis (Jönsson et al.,
2011a).
NEUTROPHILS IN ANAPHYLAXIS
Passive anaphylaxis is a highly sensitive and convenient mean
to study anaphylactic antibodies. Naive animals injected with
speciﬁc antibodies, however, differ markedly from actively immu-
nized animals. We therefore investigated molecular and cellular
mechanisms that account for ASA using FcR-deﬁcient mice.
ASA REQUIRES NEITHER FcεRI NOR FcγRIIIA
We found ﬁrst that, when immunized with antigen in Freund’s
adjuvant, mice produced not only high amounts of speciﬁc IgG1
and (much) lower amounts of IgG2 but also some IgE, whereas
mice immunized with antigen in alum produced high amounts
of IgG1 and some IgE, but no detectable IgG2. Surprisingly,
mice lacking either IgE receptors (both FcεRI and FcεRII) or
FcγRIIIA underwent similar shocks as wt mice when immunized
with antigen in Freund’s adjuvant and challenged with antigen
intravenously. Even more surprisingly,when immunized and chal-
lenged under the same conditions, quintuple knock-out (5KO)
mice lacking FcεRI, FcεRII, FcγRI, FcγRIIB, and FcγRIIIA, under-
went also anaphylactic shocks of similar intensity and leading to
similar mortality as wt mice.
ASA MAY BE INDUCED BY IgG2 ANTIBODIES VIA FcγRIV
The only known FcR expressed by 5KO mice are FcRn and
FcγRIV. Evidence that FcγRIV were responsible for the shocks
was obtained using FcγRIV-speciﬁc blocking antibodies that
abrogated both clinical symptoms and mortality. FcγRIV are
high-afﬁnity receptors that bind IgG2, but not IgG1 (Nimmer-
jahn et al., 2005; Mancardi et al., 2008). This suggested that
IgG2, but not IgG1, antibodies were responsible for ASA in
5KO mice immunized with antigen in Freund’s adjuvant. Indeed,
5KO mice underwent no ASA if immunized with antigen in
alum.
NEUTROPHILS ARE NECESSARY AND SUFFICIENT FOR
FcγRIV-DEPENDENT ASA
FcγRIV are expressed by monocyte/macrophages and neutrophils,
but not by mast cells, basophils, or eosinophils.We therefore inves-
tigated the possible contribution of these two cell types. Mono-
cyte/macrophage depletion by clodronate-containing liposomes
or inactivation by gadolinium had no effect on ASA in 5KO mice
immunized in Freund’s adjuvant. However, neutrophil depletion
with anti-Gr1 antibodies abrogated ASA in these mice. Notice-
ably, neutrophil depletion was transient, and ASA was restored
spontaneously as neutrophil numbers returned to normal. Sup-
porting this correlation, a rapid systemic release of myeloper-
oxidase could be observed in 5KO mice injected with luminol
intraperitoneally before being challenged forASA. Finally, demon-
strating the role of neutrophils, ASA, which was abrogated in
FcRγ-deﬁcient mice, was restored by an intravenous injection of
puriﬁed neutrophils from 5KO mice, but not from FcRγ-deﬁcient
mice.
NEUTROPHILS PLAY A DOMINANT ROLE IN ASA IN WT MICE
If neutrophils account for ASA in 5KO mice, they may not
be critical in wt mice. We therefore examined the effect of
depleting neutrophils, basophils, or both on ASA in wt mice.
Basophil depletion had a mild effect on body temperature drop
and on mortality observed following antigen challenge. Neu-
trophil depletion had a more marked effect on temperature
drop and mortality. The depletion of both neutrophils and
basophils had a more marked effect on temperature drop and
the same effect on mortality. Both cell types therefore con-
tribute to ASA in wt mice, but neutrophils play a dominant
role.
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NEUTROPHILS CAN INDUCE IgG–PSA
If as discussed above, mast cells are the effector cells of IgE-
induced PSA, (Metcalfe et al., 2009; Kalesnikoff and Galli, 2010),
cells responsible for IgG1–PSA have not been formally identiﬁed.
We found that neutrophils can play a major role in IgG–PSA.
Immune complexes made of GPI and polyclonal IgG anti-GPI
antibodies or of DNP-HSA and monoclonal IgG2b anti-DNP
antibodies could indeed induce anaphylaxis when injected i.v.
into 5KO mice. This FcγRIV-dependent IgG2–PSA was abro-
gated following neutrophil but not monocyte/macrophage deple-
tion. Neutrophils are therefore not only capable of inducing
ASA, they can also induce IgG2–PSA. Whether they can con-
tribute to IgG1–PSA was not investigated. It is a likely possibility
since FcγRIIIA, whose deletion sufﬁced to abrogate this reac-
tion (our unpublished data) and which bind efﬁciently IgG1
immune complexes (Figure 3), are expressed inmouse neutrophils
(Figure 4).
HUMAN NEUTROPHILS CAN INDUCE ASA
Noticeably, ASA could be restored by injecting actively immu-
nized FcRγ-deﬁcient mice not only with mouse neutrophils, but
also with human neutrophils from normal donors shortly before
antigen challenge. No shockwas induced in non-immunizedmice,
excluding that human neutrophils were non-speciﬁcally activated
in mouse blood, and the magnitude of temperature drop was pro-
portional to the amount of human neutrophils injected in immu-
nized mice. Supporting these in vivo ﬁndings, human neutrophils
could be activated in vitro by preformed immune complexes made
with mouse IgG1 or IgG2, as assessed by the down regulation of
CD62L expression.
FcγRIIA CAN TRIGGER ANAPHYLAXIS
Human neutrophils do not express FcγRIV that do not exist in
humans. They however express two IgG receptors: the ITAM-
containing single-chain FcγRIIA and the GPI-anchored FcγRIIIB
that do not exist in mice. Because FcγRIIA, but not FcγRIIIB, have
cell-activating capabilities and because FcγRIIA,but not FcγRIIIB,
bind immune complexes made with mouse IgG antibodies, we
investigated the role of FcγRIIA in ASA.
To this end, we crossed human FcγRIIA-transgenic
(FcγRIIATg) mice with FcRγ-deﬁcient mice. Importantly, because
it was placed under the control of its own promoter, FcγRIIA
had the same tissue distribution in transgenic mice as in humans.
When actively immunized and challenged with antigen, FcRγ−/−
FcγRIIATg mice underwent ASA of comparable magnitude as
wt mice (Figure 5), and both temperature drop and mortality
were abrogated by treating mice with the blocking anti-FcγRIIA
antibody IV.3. ASA can therefore be triggered by FcγRIIA. Cells
responsible for FcγRIIA-dependent ASA were not identiﬁed. Sim-
ilar results were observed in FcRγ−/− FcγRIIATg mice immunized
with antigen in Freund’s adjuvant, which induces both IgG1 and
IgG2 antibodies, or with antigen in Alum, which induces IgG1
antibodies only. FcγRIIA has indeed an afﬁnity for both mouse
IgG1 and IgG2 (our unpublished data).
To further investigate the role of FcγRIIA in anaphylaxis,
we crossed FcγRIIATg mice with 5KO or 3KO (lacking FcγRI,
FcγRIIB, and FcγRIIIA) mice. One advantage of the latter two
mutant mice is that they express FcγRIV whereas FcRγ−/−
FcγRIIATg mice do not. This activating receptor can be used
for depletion experiments with IgG2 antibodies, but it will not
be engaged if IgG1 antibodies are used for anaphylaxis. Con-
versely, FcRγ−/− FcγRIIATg mice express FcγRIIB whereas 3KO-
FcγRIIATg and 5KO-FcγRIIATg mice do not. IgG-induced reac-
tions are therefore not submitted to FcγRIIB-dependent inhibition
in these mice (Figure 5).
IgG–PSA could be induced in both 3KO-FcγRIIATg and 5KO-
FcγRIIATg mice and, as expected, shocks observed in these mice
were more severe than shocks observed in FcRγ−/− FcγRIIATg
mice. Likewise, IgG–PCA could be induced in 5KO-FcγRIIATg
mice injected with heat-aggregated polyclonal human IgG or with
ova-mouse IgG1 anti-ova immune complexes i.d. (Figure 5). In
accordance with these ﬁndings, PCMC from 3KO-FcγRIIATg mice
degranulated, released granularmediators and secreted lipidmedi-
ators upon challenge with ova-IgG1 anti-ova or with GPI–IgG
FIGURE 5 | Anaphylactic properties of FcγRIIATg in FcR-KO mice.The ﬁgure shows the expression of FcR in FcgRIIATg mice used in our studies (left) and the
magnitude of their responses in four models of anaphylaxis (right).
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anti-GPI immune complexes. To conﬁrm that, as suggested by
these results,mast cells account for FcγRIIA-dependent PCA,3KO,
and 3KO-FcγRIIATg mice were crossed with Wsh mice. PCA was
observed neither in 3KO-Wsh nor in 3KO-FcγRIIATg Wsh mice
whereas it occurred in 3KO-FcγRIIATg mice.
OTHER MYELOID CELLS IN ALLERGY
MACROPHAGE/MONOCYTES IN PSA
Contrasting with these results that altogether indicate that mast
cells are the cell type that accounts for FcγRIIA-dependent PCA,
FcγRIIA-dependent PSA developed normally in 3KO-FcγRIIATg
Wsh mice. Basophil depletion with Ba103 did not affect either
FcγRIIA-dependent PSA in 3KO-FcγRIIATg mice. Both mast cells
and basophils are therefore dispensable for FcγRIIA-dependent
PSA. GPI–IgG anti-GPI immune complex-induced PSA was how-
ever reduced following neutrophil depletion with anti-Gr1 or
anti-Ly6G antibodies in the same mice. It was also reduced follow-
ing monocyte/macrophage depletion with clodronate-containing
liposomes or inactivation with gadolinium, and abrogated follow-
ing depletion of both neutrophils and monocyte/macrophages.
Neutrophils,but alsomonocyte/macrophages therefore contribute
to FcγRIIA-dependent PSA. Both cell types express high levels of
FcγRIIA in humans (Figure 4).
A contribution of macrophages in a model of active anaphy-
laxis was previously reported. In this model, mice immunized
with goat anti-mouse IgD antibodies, which induced robust anti-
goat IgG responses, as well as mastocytosis, were challenged with
goat IgG used as an antigen. Anaphylaxis induced under these
conditions was of similar magnitude in wt mice, in IgE- or FcεRI-
deﬁcient mice, and in W/W-v mice. It was reduced in mice treated
with gadolinium, but not or in mice injected with neuraminidase,
which depletes platelets, or in mice injected with a rat IgG2b
anti-granulocyte mAb. The conclusion was that macrophages,
but not mast cells, platelets, or granulocytes accounted for this
anaphylactic reaction (Strait et al., 2002).
EOSINOPHILS IN ASTHMA
Eosinophils reside in mucosal tissues. They are well characterized
as effector cells in helminth infections (Klion and Nutman, 2004),
during which they release a panoply of different cytokines, such
as TGF-β, lipid mediators such as platelet-activating factor (PAF),
leukotriene C4 (LTC4) and other effector molecules such as major
basic protein (MBP), and eosinophil peroxidase (EPO;Kita, 2011).
These functions make the eosinophil a powerful weapon against
parasites, however their activation is often associated with detri-
mental effects on the host environment. Two allergic conditions
have been associated with eosinophil activation: allergic bronchial
asthma and eosinophilic esophagitis (EOE).
Allergic bronchial asthma is characterized by airway hyperre-
sponsiveness (AHR), bronchoobstruction, and increased mucus
production, resulting in a chronic inﬂammation and, ultimately,
in airway remodeling. Since Ehrlich (1879) described eosinophils
in tissue and sputum of patients with asthma, these cells have
been identiﬁed as the prime target of therapeutic intervention
in bronchial asthma. Indeed, eosinophils have been implicated
in all aspects of asthma pathogenesis. Whereas MBP and EPO
can cause tissue destruction and AHR, PAF and LTC4 are potent
bronchoconstrictors and increase mucus production, and TGF-β
is thought to contribute to airway remodeling. Various strategies
that interfere with eosinophil recruitment, activation, and survival
have been proven successful in animal models of experimental
asthma. These strategies included inhibition of eosinophil recruit-
ment and activation by targeting IL-5 (Foster et al., 1996; Yoshida
et al., 1996; Lee et al., 1997), CD131 (Nicola et al., 1996; Sun et al.,
1999), CD300a (Munitz et al., 2006), CD23 (Dasic et al., 1999;
Haczku et al., 2000), CD48 (Munitz et al., 2007), CCR-3 (Pope
et al., 2005; Wegmann et al., 2007), or PGD2 signaling (Sugimoto
et al., 2003; Uller et al., 2007; Shichijo et al., 2009; Stearns et al.,
2009). Other strategies aimed at reducing eosinophil numbers by
using mAbs anti-CCR-3 (Justice et al., 2003) or mAbs anti-Siglec
F (Song et al., 2009). Although all of these approaches amelio-
rated the symptoms of experimental asthma in mice, the ﬁrst
clinical trials targeting IL-5 (Leckie et al., 2000; Flood-Page et al.,
2003, 2007), CD23 (Rosenwasser and Meng, 2005), CCR-3 (Pease
and Horuk, 2009), and/or CD131 (Gauvreau et al., 2008) did not
meet the therapeutic expectations. This might have been due to
the fact that experimental asthma models in mice often strictly
dependonairwayhypereosinophilia and, therefore,maynot reﬂect
human asthma. Recently however, two studies reported a sig-
niﬁcant improvement of severe corticosteroid-refractory highly
eosinophilic asthma, using an anti-IL-5 mAb (Haldar et al., 2009;
Nair et al., 2009).
Eosinophilic esophagitis is an atopic disease linked to ingested
and inhaled allergens. It is characterized by an eosinophilic inﬁl-
trate in the mucosa of the esophagus that can result in a narrowed
esophageal lumen (Liacouras et al., 2011). Patients suffer fromdys-
phagia, heartburn, or chest pain. In most cases EoE is associated
with other forms of allergy like, asthma, hay fever, or eczema.
Common treatments consist of dietary elimination and topi-
cal administration of corticosteroids or ﬂuticasone propionate,
which mobilizes the eosinophilic inﬁltrate, and improve symp-
toms (Remedios et al., 2011). Anti-IL-5 mAb (Assa’Ad et al., 2011)
and leukotriene receptor antagonists (Lucendo et al., 2011) have
also been used with variable successes.
MAST CELLS AND COMPANY
Considering the variety of antibodies, receptors, and cells that
were found to be involved in experimental models of anaphy-
laxis (Table 2), the long accepted IgE/FcεRI/mast cell paradigm,
on which the deﬁnition of immediate hypersensitivity is based in
the Gell and Coomb’s classiﬁcation, and on which most therapeu-
tic approaches of allergy depend, appears much too reductionist.
One must consider not only IgE but also IgG antibodies, not
only FcεRI, but also FcγR of the different types, not only mast
cells and basophils but also neutrophils,monocytes,macrophages,
eosinophils, and possibly other myeloid cells.
IgE/MAST CELLS AND IgG/MYELOID CELLS IN ANAPHYLAXIS
The most surprising conclusion of the works discussed in this
review is that the IgE/FcεRI/mast cell paradigm has probably a
minor contribution, if any, in ASA. Indeed, ASA developed nor-
mally in the absence of IgE, in FcεRI-deﬁcient mice, and in mice
lacking mast cells. IgG antibodies (not only IgG1, but also IgG2),
FcγR (not only FcγRIIIA whose deletion did not prevent ASA,
but also FcγRIV), and granulocytes (not only basophils whose
depletion hardly diminished the magnitude of ASA, but essentially
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Table 2 | Antibodies, receptors, and cells involved in experimental anaphylaxis.
Assay Ab classes FcRs Cells FcγRIIATg
ASA
Freund IgGl> IgG2 IgE FcγRIIIA+ IV Neutros>basos;
not monos, eosinos
Yes cells?
Alum IgGl IgE FcγRIIIA ND Yes cells?
PSA
IgE FcεRI Mast cells ND
IgGl FcγRIIIA Basos and? Yes cells?
lgG2b FcγRIV Neutros ND
Immune serum FcγRIIIA+ IV Neutros Yes monos>neutros;
not basos, mast cells, eosinos
PCA
IgE FcεRI Mast cells ND
IgGl FcγRIIIA Mast cells Yes mast cells
IgG2b ? ? ND
Polyclonal IgG FcγRIIIA ? Yes
ND, not determined.
neutrophils) appeared as the major players that were involved in
and accounted for ASA. One can argue that this conclusion lies
on the results of experiments done in murine models that may
not faithfully mimic anaphylactic shocks observed in patients.
Mice were immunized by repeated injections of relatively high
amounts of antigen in Freund’s adjuvant or in alum, which favors
IgG responses rather than IgE responses. The role of IgG2 antibod-
ies could be unraveled using mice that expressed IgG2 receptors
only, and this antibody subclass is quantitatively minor in mouse
immune responses. The blocking of FcγRIV, however, reduced
ASA, albeit less than the deletion of FcγRIIIA that bind both IgG1
and IgG2, in wt mice immunized with antigen in Freund’s adju-
vant. IgG1 are several-fold more abundant than IgG2 in serum
from normal and immunized mice, even following immunization
in Freund’s adjuvant. They are exceedingly more abundant than
IgE in mice, whatever the immunization protocol used, but also in
humans, including in allergic patients.
ASA AND PSA
Another unexpected ﬁnding is that PSA does not appear as an
accurate model of ASA. Passive anaphylaxis (PSA in experimental
animals and, later, the Prausnitz–Küstner reaction, its equivalent
in humans) was developed soon after Richet (1907) demonstrated
that anaphylactic sensitization could be passively transferred by
the serum of actively immunized animals. A major difference
is that the immune system of animals injected with antibodies
has not “seen” antigen before challenge, whereas that of immu-
nized animals has previously mounted a speciﬁc adaptive immune
response, with all its effectors, and it reacts for the second time
to antigen, with these effectors, when challenged with antigen.
Another difference is that a whole array of antibodies, with rela-
tively well deﬁned respective concentrations, have been generated
in immunized animals, whereas antibodies of a single class are
usually injected into recipients, especially since monoclonal anti-
bodies became available. Under these conditions, speciﬁc FcR
are targeted by antibodies of one class or another and, in most
cases, speciﬁc cell types, depending on the FcR they express.
Thus, passively administered IgE target primarily FcεRI that are
exclusively expressed by mast cells and basophils in mice. Why
mast cells, but not basophils, account for IgE–PSA is unclear.
IgG1 antibodies target FcγRIIIA, which are the only activat-
ing FcR that bind this antibody subclass in mice. FcγRIIIA are
widely expressed by mouse cells, and not only by mast cells and
basophils. Why neither mast cells nor, possibly, basophils seem
to account for IgG1–PSA is unknown, as well as the responsi-
ble cell type. IgG2 antibodies target FcγRIIIA as well, but also
FcγRIV that are expressed by monocyte/macrophages and neu-
trophils only. Why IgG2–PSA involves neutrophils, but neither
monocyte/macrophages,which also express FcγRIIIA and FcγRIV,
nor mast cells or basophils, which express FcγRIIIA, may possibly
be explained by the crosstalk between activating and inhibitory
receptors.
ACTIVATING FcR AND INHIBITORY FcR
IgG antibodies engage both activating and inhibitory receptors,
depending on the cell type, which can modulate not only IgG- but
also IgE-induced responses. This regulation does not occur when
monomeric puriﬁed IgE are injected to prepare mice for PSA. An
exampleof FcγRIIB-dependent inhibition is as follows.Monocytes
and neutrophils from wt mice express the same FcR: FcγRIIB,
FcγRIIIA, FcγRIV, and possibly FcγRI. Mouse monocytes and
neutrophils can both induce anaphylaxis. Yet, neutrophils, but
not monocytes accounted for anti-GPI serum-induced PSA in wt
mice, whereas monocytes, more than neutrophils, accounted for
the same reaction in FcγRIIATg mice. The dominant contribution
of neutrophils in wt mice can be explained by the lower expression
of FcγRIIB on neutrophils than on monocytes (Figure 4). Thus,
IgG antibody-induced activation signals of a similar magnitude
could be inhibited by FcγRIIB more efﬁciently in monocytes than
in neutrophils. Differing fromwtmice, 3KO-, and 5KO-FcγRIIATg
mice do not express FcγRIIB. Their neutrophils and their mono-
cytes expressed similar levels of transgenic FcγRIIA the activation
signals of whichwere therefore not inhibited by FcγRIIB and could
induce anaphylactic reactions of comparable magnitudes.
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THE TREE AND THE FOREST
Finally, the ﬁndings and conclusions discussed in this review are
less provocative than they may seem. Serum-induced PSA is a bet-
ter model of ASA than monoclonal antibody-induced PSA. The
reason is that both assays involve the same polyclonal antibodies.
Indeed, anti-GPI serum, which contains a whole array of poly-
clonal antibodies of the various classes and subclasses, induced
PSA that involved both the same receptors (FcγRIIIA and FcγRIV)
and the same cells (primarily neutrophils) as ASA in wt type
mice (Table 2). Serum-induced PSA, was described initially, and
later used to demonstrate that ASA depends on antibodies, before
puriﬁed antibodies, ﬁrst and, later, monoclonal antibodies were
increasingly used for PSA. If, however, it does not recapitulateASA,
monoclonal antibody-induced PSA remains a powerful analytical
tool that targets cells and receptors.
Our ﬁndings make sense if one simply keeps in mind that neu-
trophils are 100-fold more numerous than basophils in blood and
that IgG antibodies are 105- to 106-fold more abundant than
IgE antibodies in plasma. The IgE/mast cell/basophil tree was
somehow hiding the forest of IgG/myeloid cells. This change in
perspective may have important consequences.
CONCLUDING REMARKS
Indeed, allergy is not another reaction. It is not due to unique
effectors, whether molecular or cellular, that are exclusively patho-
genic, but to the same cells and molecules that concur to protective
immune responses. Allergy is an acute adaptive inﬂammatory
reaction initiated by antibodies. Inﬂammation is a physiological
defense response. It associates destruction and repair mechanisms
that are instrumental in wound healing and protection against
infection. Inﬂammation is also potentially harmful, but in nor-
mal conditions, it is kept under the control of efﬁcient regulatory
mechanisms.
Antibody-induced inﬂammation depends on a multitude of
parameters. (1) It depends ﬁrst on the presence of antigen. No
effect can be induced in the absence of antigen, even if antibodies
are present. (2) It depends on the availability of antibodies. Anti-
bodies are present in relatively high concentrations in blood and
in hematopoietic organs, but in lower concentrations in periph-
eral tissues, such as skin for instance. Local concentrations of
antibodies (e.g., IgE) can, however, be high. An example is nasal
polyps that are associated with allergic rhinitis and that contain
IgE-secreting plasma cells (Takhar et al., 2005). (3) It depends
on the isotypic composition of immune complexes at a given
time and at a given place. This composition is itself shaped by
the nature and the amount of immunizing antigen, by adjuvants,
by the route and mode of immunization. (4) It depends on the
availability of FcR on a given cell. High-afﬁnity FcR may be occu-
pied, at least in part, by antibodies of a different speciﬁcity. Some
FcR are inducible only, others can be up- and down-regulated
by cytokines. (5) It depends on the relative expression of FcRs,
especially of activating vs. inhibitory FcR, on myeloid cells that
are present at the same site. (6) It depends on the functional
repertoire of each of the cell types involved and on the cocktail
of pro-inﬂammatory mediators they can release or secrete. (7) It
depends on the availability and on the proportion of cells of the
different types that are present initially and that are recruited in
the inﬂammatory inﬁltrate. (8) It ﬁnally depends on the media-
tors that are released by effector cells upon activation and on the
target cells that express receptors for these mediators present in
the environment.
Allergies are remarkably polymorphic in their clinical expres-
sion. This polymorphism is usually explained by the location
where the acute reaction occurs and on the target cells that respond
to released and secreted mediators. It may also depend on the
nature of effector cells that are activated by antibodies and, there-
fore, on the antibody classes and subclasses. If this view is correct,
one may consider that several nosological entities are possibly
hidden behind that of allergy. One may therefore envision that
the therapeutic approaches of allergies be diversiﬁed, whether
symptomatic or etiologic, and adapted to the effector cells and
molecules involved. An antihistamine treatment, for instance,may
be efﬁcient in a mast cell-dependent reaction, but much less in a
neutrophil-dependent reaction.
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